| Osteopontin as a therapeutic target for cancer M Bandopadhyay, A Bulbule, R Butti, G Chakraborty, P Ghorpade, ... Expert opinion on therapeutic targets 18 (8), 883-895, 2014 | 145 | 2014 |
| Osteopontin: a potentially important therapeutic target in cancer M Ahmed, R Behera, G Chakraborty, S Jain, V Kumar, P Sharma, ... Expert opinion on therapeutic targets 15 (9), 1113-1126, 2011 | 86 | 2011 |
| Role of osteopontin in tumor microenvironment: a new paradigm in cancer therapy R Butti, P Ghosh, KVS Totakura, RNN Venkata, R Nimma, GC Kundu Multi-Targeted Approach to Treatment of Cancer, 113-125, 2015 | 12 | 2015 |
| Multi-targeted approach to treatment of cancer V Gandhi, K Mehta, R Grover, S Pathak, BB Aggarwal Springer International Publishing, 2015 | 11 | 2015 |
| Therapeutic Targeting of Osteopontin in Breast Cancer Cells GC Kundu Edited by Esra Gunduz and Mehmet Gunduz, 23, 2011 | 4 | 2011 |
| Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of acquired resistance YE Stern, P Ghosh, HS Solanki, D Imbody, L Bridenstine, ... MOLECULAR CANCER RESEARCH 21 (5), 2023 | | 2023 |
| Abstract B035: Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of … YE Stern, P Ghosh, HS Solanki, D Imbody, L Bridenstine, ... Molecular Cancer Research 21 (5_Supplement), B035-B035, 2023 | | 2023 |
| Abstract B028: CDK12/13 inhibition antagonizes resistance to KRASG12C inhibitors YE Stern, P Ghosh, HL Walker-Mimms, JW Mosior, D Imbody, HS Solanki, ... Cancer Research 82 (23_Supplement_2), B028-B028, 2022 | | 2022 |
